Intelligence / Healthtech / New Clinical Trials / Beijing Konruns Pharmaceutical Co., Ltd.
Clinicaltrial registered16 Nov 2026
Beijing Konruns Pharmaceutical Co., Ltd.
16 Nov 2026: Trial registered · KC1086 in Combination With Fulvestrant for HR-Positive, HER2-Negative Advanced Breast Cancer. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 16 Nov 2026
- Title
- KC1086 in Combination With Fulvestrant for HR-Positive, HER2-Negative Advanced Breast Cancer
- Conditions
- HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
- Phase
- Phase 2
- Study Type
- Interventional
- Status
- Not Yet Recruiting
- Reference
- NCT07937605
What this signal means
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS
Find the decision makers at Beijing Konruns Pharmaceutical Co., Ltd.
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.